Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME
Baylor Scott & White Health, Dallas (United States of America)
116
presentations
17
followers
5
more
presentations
in this session
Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study
Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials
Marked variation in the efficacy of beta-blockers across cardiovascular health: A Global systematic assessment of mortality, myocardial infarction and stroke
Predicting right heart failure after implantation of continuous flow left ventricular assist devices (EUROMACS-RHF) score: analysis of the EUROMACS data